SILO Pharma Inc Dossier - Source-backed chat

SILO Pharma Inc

SILONASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.83

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.50Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2.6M

Enterprise Value −$2.1M

Shares Outstanding 1.8M diluted

Next Earnings Date13 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Silo Pharma, Inc. is a developmental-stage biopharmaceutical company focused on next-generation central nervous system (CNS) and psychedelic-assisted therapeutics. The company has successfully resolved its near-term delisting risk by regaining Nasdaq compliance on June 17, 2026, following a 1-for-15 reverse stock split. While its lead candidate, SPC-15 (an intranasal prophylactic for PTSD), is progressing toward a first-in-human Phase 1 clinical trial in collaboration with Allucent, the company remains pre-revenue and highly speculative. Additionally, Silo has diversified into highly volatile digital assets and recently acquired the QwikAgents AI platform, introducing non-core operational risks. Given the early stage of its clinical pipeline and the speculative nature of its treasury strategy, a Hold recommendation is warranted until clinical data or regulatory milestones are achieved.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The FDA issues a clinical hold or requests additional preclinical studies for SPC-15, delaying the Phase 1 trial. High cash burn from R&D and further write-downs on digital asset holdings deplete liquidity, forcing highly dilutive equity raises. The stock price falls back below $1.00, renewing delisting pressures.

Base CaseCentral scenario

The company successfully files its IND for SPC-15 in 2026 and initiates its Phase 1 clinical trial. Cash reserves of approximately $3.9 million, supplemented by short-term investments, provide sufficient runway for the next 12 months of R&D. The stock price stabilizes above the Nasdaq minimum requirement, and the QwikAgents AI platform begins to show integration value in drug discovery.

Bull CaseUpside scenario

Silo Pharma presents a compelling dual-growth narrative combining its clinical-stage biopharmaceutical pipeline with a newly established enterprise AI platform. Its lead therapeutic candidate, SPC-15, is a novel intranasal PTSD treatment backed by exclusive global licensing from Columbia University and a strong IP portfolio. Concurrently, its wholly owned subsidiary QwikAgents is preparing to commercially launch its autonomous AI agent platform within 60 to 90 days, creating a near-term revenue-generating technology franchise alongside long-term clinical catalysts.

Scenarios reflect our research view at the research date.

Key Investment Merits

Lead candidate SPC-15 targets PTSD, a high-unmet-need market with no new drug approvals in nearly 25 years.
Partnership with Allucent, a global CRO, provides robust clinical execution support for upcoming Phase 1 trials.
Regained Nasdaq compliance removes immediate delisting overhang and stabilizes public market access.
Utilization of the FDA's 505(b)(2) accelerated regulatory pathway could shorten clinical timelines and reduce development costs.

Key Investment Risks

Pre-revenue developmental stage with ongoing net losses ($1.65 million in Q1 2026) and high cash burn.
Speculative corporate treasury strategy with exposure to highly volatile digital assets (Bitcoin, Ethereum, Solana, ResearchCoin).
Potential for significant shareholder dilution through future equity offerings to fund clinical trials.
Inherent clinical development risks, including potential regulatory delays or unfavorable trial outcomes.

Thesis Invalidation Triggers

FDA rejection or prolonged clinical hold on the SPC-15 IND application.
Severe liquidity depletion where cash and short-term investments fall below $2 million without a clear path to non-dilutive funding.
A sustained decline in the stock price below $1.00, triggering another Nasdaq non-compliance notice.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.